96 related articles for article (PubMed ID: 10851507)
1. Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial.
Tourani JM; Grise P; Lucas V; Mayeur D; Dufour B; Di Palma M; Boaziz C; Pavlovitch JM; Pujade-Lauraine E; Larregain D; Untereiner M
Cancer Biother Radiopharm; 1996 Oct; 11(5):297-300. PubMed ID: 10851507
[No Abstract] [Full Text] [Related]
2. Aldesleukin for metastatic renal cell carcinoma?
Drug Ther Bull; 1993 Apr; 31(8):29-30. PubMed ID: 8348884
[No Abstract] [Full Text] [Related]
3. Interleukin-2.
Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
[No Abstract] [Full Text] [Related]
4. Improving the therapeutic index of IL-2.
McDermott DF
Clin Adv Hematol Oncol; 2010 Dec; 8(12):862-4. PubMed ID: 21326162
[No Abstract] [Full Text] [Related]
5. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
6. [Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program].
Tourani JM; Jaillon-Abraham C; Lucas V; Chrétien Y; Mayeur D; Di Palma M; Boaziz C; Grise P; Varette C; Pavlovitch JM; Larregain D; Ecstein E; Untereiner M; Andrieu JM
Bull Cancer; 1997 Apr; 84(4):351-6. PubMed ID: 9238157
[TBL] [Abstract][Full Text] [Related]
7. Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.
Martens A; Janssen RA; Sleijfer DT; Heijn AA; Mulder NH; The TH; de Leij L
Br J Cancer; 1993 May; 67(5):1118-21. PubMed ID: 8494709
[TBL] [Abstract][Full Text] [Related]
8. Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial.
Veelken H; Rosenthal FM; Schneller F; von Schilling C; Guettler IC; Herrmann F; Mertelsmann R; Lindemann A
Biotechnol Ther; 1992; 3(1-2):1-14. PubMed ID: 1305889
[TBL] [Abstract][Full Text] [Related]
9. Of snails and holy grails..
Yang JC
Cancer J Sci Am; 1997; 3(3):142-3. PubMed ID: 9161778
[No Abstract] [Full Text] [Related]
10. FDA approves release of recombinant interleukin-2 product.
Clin Pharm; 1992 Aug; 11(8):669-70. PubMed ID: 1511538
[No Abstract] [Full Text] [Related]
11. Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma.
Deshpande H; Dutcher JP; Novik Y; Oleksowicz L
Cancer J Sci Am; 1999; 5(1):52-3. PubMed ID: 10188062
[No Abstract] [Full Text] [Related]
12. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
Gardner TA; Logan T
J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
[No Abstract] [Full Text] [Related]
14. Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy.
Diner EK; Linehan M; Walther M
Int J Urol; 2005 Nov; 12(11):996-7. PubMed ID: 16351658
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
16. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2.
Buter J; Sleijfer DT; van der Graaf WT; de Vries EG; Willemse PH; Mulder NH
Semin Oncol; 1993 Dec; 20(6 Suppl 9):16-21. PubMed ID: 8284687
[No Abstract] [Full Text] [Related]
17. [Advice from Public Health Council concerning administration of interleukin-2 in patients with renal cell tumor].
van Maanen L
Oncologica; 1994 May; 11(2):31-2. PubMed ID: 8025832
[No Abstract] [Full Text] [Related]
18. High-dose interleukin-2 in metastatic renal cell carcinoma.
Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
[No Abstract] [Full Text] [Related]
19. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
[TBL] [Abstract][Full Text] [Related]
20. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
